CD163 and metabolic dysfunction-associated steatotic liver disease: When evaluating the treatment arms according to presence and absence of steatosis, the liraglutide-treated group with NAFLD experienced decreased sCD163 levels, however, this difference was not significantly different from that of the placebo NAFLD group, suggesting that liraglutide has no effect on this parameter in women with pGDM and NAFLD per se.